N/A N=27 Tissue Penetration of Antibiotics in Obesity
Obesity
Primary: Cefoxitin Plasma Concentrations — 89; 81 (µg/mL) — p=<0.05
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=42 Adjuvant Benefit of NMES to Supervised Exercise in Patients With IC
Intermittent Claudication · Peripheral Vascular Disease · Lower Limb Arterial Disease
Primary: Initial Walking Distance Measured by Treadmill — 65.60; 95.50 metres
Phase 1 N=24 Safety Study of Intratumoral Injection of Clostridium Novyi-NT Spores to Treat Patients With Solid Tumors That Have Not Responded to Standard Therapies
Solid Tumor Malignancies
Primary: Number of Patients With Treatment-emergent Adverse Events (TEAE) — 3; 3; 4; 6 Patients
N/A N=12 "Hub and Satellite" Heart Failure Provider's Network Study
Heart Failure
Primary: Number of Superior Heart Failure Performance Outcome Quality Measures — 5; 4 number of outcome measures superior
N/A N=25 The Effect of Fruit/Vegetable Drinks on the Human Intestine
Intestinal Bacteria Flora Disturbance
Primary: Change in Colonic Flora Composition — 52.4; 41.2; 41.4; 51.9 percentage of total bacteria — p=0.014
Phase 1 N=74 Study to Evaluate Safety, Tolerability and Pharmacokinetics of rhNGF Eye Drops in Healthy Volunteers
Healthy
Primary: Changes in VAS Ocular Tolerability — -1; 0; 0; 3 units on a scale
Phase 2 N=10 Dasatinib In Combination With Trastuzumab And Paclitaxel In First Line Treatment Of Her2-Positive MBC Patients
Metastatic Breast Cancer
Primary: Number of Participants With Dose Limiting Toxicity (DLT) Within the First Cycle of Dasatinib in Combination With Trastuzumab and Paclitaxel (Phase I) — 1; 2 Participants
Phase 4 N=498 Multi-center Study to Evaluate the Safety of Apixaban (BMS-562247) in Indian Subjects Undergoing Elective Total Knee Replacement or Total Hip Replacement Surgery
Anticoagulation
Primary: Number of Participants With Composite of International Society on Thrombosis and Haemostasis (ISTH) Major Bleeding/Clinically Relevant Non-major Bleeding (CRNM) While…
Phase 4 N=97 Decreasing Postoperative Blood Loss by Topical vs. Intravenous Tranexamic Acid in Open Cardiac Surgery
Bleeding · Surgical Blood Loss
Primary: Median Volume of Mediastinal Fluid Collected From Participants — 500; 540 mL
Phase 1 N=17 Alisertib and Fractionated Stereotactic Radiosurgery in Treating Patients With Recurrent High Grade Gliomas
Adult Anaplastic Astrocytoma · Adult Anaplastic Ependymoma · Adult Anaplastic Oligodendroglioma
Primary: Maximum Tolerated Dose (MTD) of Alisertib — 50 mg dose of Alisertib
N/A N=180 Brief Alcohol Intervention for HIV-Infected Men Who Have Sex With Men (MSM) in a Primary Care Setting
Hazardous Drinking · HIV
Primary: Number of Alcoholic Drinks Consumed — 11.6; 7.2 drinks per week — p=.04
N/A N=360 Improving the Frequency and Quality of Sleep Apnea Care Management
Obstructive Sleep Apnea
Primary: Positive Airway Pressure Adherence — 3.9; 3.9; 3.8 Hours
Phase 2 N=42 An 8-Week Dose-Finding Study to Evaluate the Efficacy and Safety of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia
Hypercholesterolaemia
Primary: Percent Change From Baseline in Calculated Low Density Lipoprotein Cholesterol (LDL-C) at Week 8 — -41.1; -7.9; -40.6; -49.8 percent change
N/A N=33 Long-pulsed 1064 nm Nd:YAG Laser Treatment of Basal Cell Carcinoma
Basal Cell Carcinoma
Primary: This is a Study to Measure the Efficacy of the Nd:YAG Laser to Cause Complete Regression of Basal Cell Carcinoma. — 28 tumors
Phase 2 N=44 Targeted Anticoagulation Therapy to Reduce Inflammation and Cellular Activation in Long-term HIV Disease
Inflammation · Coagulation · HIV Infection
Primary: Change in Interleukin 6 (IL-6) Plasma Levels From Baseline to 4 Months. — -0.02; 0.09 ln-pg/mL — p=0.26